BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26297278)

  • 1. Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization.
    Sallman DA; Padron E
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S50-5. PubMed ID: 26297278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
    Padron E; Steensma DP
    Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].
    Harada Y; Harada H
    Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.
    Gelsi-Boyer V; Trouplin V; Roquain J; Adélaïde J; Carbuccia N; Esterni B; Finetti P; Murati A; Arnoulet C; Zerazhi H; Fezoui H; Tadrist Z; Nezri M; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
    Br J Haematol; 2010 Nov; 151(4):365-75. PubMed ID: 20880116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice.
    Patnaik MM; Tefferi A
    Mayo Clin Proc; 2016 Feb; 91(2):259-72. PubMed ID: 26848006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myelomonocytic leukemia: myeloproliferative variant.
    Onida F; Beran M
    Curr Hematol Rep; 2004 May; 3(3):218-26. PubMed ID: 15087071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis.
    Zhao W; Zhang C; Li Y; Li Y; Liu Y; Sun X; Liu M; Shao R
    Hematology; 2022 Dec; 27(1):367-378. PubMed ID: 35306971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.
    McCullough KB; Patnaik MM
    Curr Hematol Malig Rep; 2015 Sep; 10(3):292-302. PubMed ID: 26122388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CMML: a biologically distinct myeloproliferative disease.
    Cortes J
    Curr Hematol Rep; 2003 May; 2(3):202-8. PubMed ID: 12901341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
    Lin Y; Zheng Y; Wang ZC; Wang SY
    Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
    Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T
    J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review.
    Patnaik MM; Parikh SA; Hanson CA; Tefferi A
    Br J Haematol; 2014 May; 165(3):273-86. PubMed ID: 24467717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.
    Parikh SA; Tefferi A
    Am J Hematol; 2013 Nov; 88(11):967-74. PubMed ID: 23963888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic determinants of chronic myelomonocytic leukemia.
    Patel BJ; Przychodzen B; Thota S; Radivoyevitch T; Visconte V; Kuzmanovic T; Clemente M; Hirsch C; Morawski A; Souaid R; Saygin C; Nazha A; Demarest B; LaFramboise T; Sakaguchi H; Kojima S; Carraway HE; Ogawa S; Makishima H; Sekeres MA; Maciejewski JP
    Leukemia; 2017 Dec; 31(12):2815-2823. PubMed ID: 28555081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How I diagnose and treat chronic myelomonocytic leukemia.
    Patnaik MM
    Haematologica; 2022 Jul; 107(7):1503-1517. PubMed ID: 35236051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.
    Muramatsu H; Makishima H; Maciejewski JP
    Semin Oncol; 2012 Feb; 39(1):67-73. PubMed ID: 22289493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
    Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
    Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.
    Carr RM; Patnaik MM
    Curr Opin Hematol; 2020 Jan; 27(1):2-10. PubMed ID: 31688455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current management of patients with chronic myelomonocytic leukemia.
    Alfonso A; Montalban-Bravo G; Garcia-Manero G
    Curr Opin Oncol; 2017 Jan; 29(1):79-87. PubMed ID: 27849645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.